Anti–Interleukin‐6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty‐Five Patients - Concepedia

Concepedia

Publication | Closed Access

Anti–Interleukin‐6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty‐Five Patients

150

Citations

33

References

2016

Year

V. Calvo-Río, Inmaculada Calvo, María Isabel González, Berta López‐Montesinos, Marina Mesquida, Alfredo Adán, M.V. Hernández, O. Maíz, A. Atanes, Beatriz Navarro Bravo,

Arthritis & Rheumatology

Abstract

TCZ appears to be a useful therapy for severe refractory JIA-associated uveitis.

References

	Year	Citations

Page 1